GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (BSP:U2TH34) » Definitions » Beneish M-Score

United Therapeutics (BSP:U2TH34) Beneish M-Score : -2.46 (As of Apr. 16, 2025)


View and export this data going back to 2023. Start your Free Trial

What is United Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.46 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for United Therapeutics's Beneish M-Score or its related term are showing as below:

BSP:U2TH34' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -2.45   Max: -1.72
Current: -2.46

During the past 13 years, the highest Beneish M-Score of United Therapeutics was -1.72. The lowest was -2.90. And the median was -2.45.


United Therapeutics Beneish M-Score Historical Data

The historical data trend for United Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Beneish M-Score Chart

United Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.70 -2.32 -2.44 -2.03 -2.46

United Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.03 -1.39 -2.42 -2.18 -2.46

Competitive Comparison of United Therapeutics's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Beneish M-Score falls into.


;
;

United Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of United Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9085+0.528 * 0.9966+0.404 * 0.8586+0.892 * 1.3725+0.115 * 0.9621
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0852+4.679 * -0.007876-0.327 * 0.6504
=-2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was R$1,704 Mil.
Revenue was 4489.726 + 4147.258 + 3850.523 + 3374.81 = R$15,862 Mil.
Gross Profit was 4026.66 + 3687.067 + 3431.484 + 3011.783 = R$14,157 Mil.
Total Current Assets was R$23,635 Mil.
Total Assets was R$44,928 Mil.
Property, Plant and Equipment(Net PPE) was R$7,458 Mil.
Depreciation, Depletion and Amortization(DDA) was R$401 Mil.
Selling, General, & Admin. Expense(SGA) was R$3,520 Mil.
Total Current Liabilities was R$4,503 Mil.
Long-Term Debt & Capital Lease Obligation was R$0 Mil.
Net Income was 1838.231 + 1711.734 + 1497.874 + 1526.807 = R$6,575 Mil.
Non Operating Income was -52.469 + -328.392 + 4.309 + 8.964 = R$-368 Mil.
Cash Flow from Operations was 2081.661 + 2088.858 + 1250.652 + 1874.895 = R$7,296 Mil.
Total Receivables was R$1,367 Mil.
Revenue was 3011.907 + 3009.644 + 2895.232 + 2640.239 = R$11,557 Mil.
Gross Profit was 2664.021 + 2663.441 + 2584.11 + 2367.83 = R$10,279 Mil.
Total Current Assets was R$17,399 Mil.
Total Assets was R$35,117 Mil.
Property, Plant and Equipment(Net PPE) was R$5,122 Mil.
Depreciation, Depletion and Amortization(DDA) was R$265 Mil.
Selling, General, & Admin. Expense(SGA) was R$2,364 Mil.
Total Current Liabilities was R$3,941 Mil.
Long-Term Debt & Capital Lease Obligation was R$1,470 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1704.009 / 15862.317) / (1366.554 / 11557.022)
=0.107425 / 0.118244
=0.9085

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10279.402 / 11557.022) / (14156.994 / 15862.317)
=0.889451 / 0.892492
=0.9966

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (23634.664 + 7457.862) / 44927.764) / (1 - (17399.19 + 5122.251) / 35116.867)
=0.307944 / 0.358672
=0.8586

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=15862.317 / 11557.022
=1.3725

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(264.699 / (264.699 + 5122.251)) / (401.379 / (401.379 + 7457.862))
=0.049137 / 0.051071
=0.9621

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3520.442 / 15862.317) / (2363.624 / 11557.022)
=0.221937 / 0.204518
=1.0852

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 4503.148) / 44927.764) / ((1469.94 + 3941.399) / 35116.867)
=0.100231 / 0.154095
=0.6504

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(6574.646 - -367.588 - 7296.066) / 44927.764
=-0.007876

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

United Therapeutics has a M-score of -2.23 suggests that the company is unlikely to be a manipulator.


United Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics Business Description

Traded in Other Exchanges
Address
1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Headlines

No Headlines